Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, announces the successful closing of the divestiture of Aadi Subsidiary, Inc. (“Aadi Sub”) to Kaken Pharmaceuticals (“Kaken”) for a cash payment of $100 million plus certain customary adjustments, completing the strategic transformation first announced in December 2024. Kaken assumes ownership of Aadi Sub, including the Aadi Bioscience name, trademarks and the FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) business.
Read the full article: Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals //
Source: https://www.prnewswire.com/news-releases/whitehawk-therapeutics-completes-strategic-transformation-with-successful-closing-of-sale-of-aadi-subsidiary-to-kaken-pharmaceuticals-302411424.html